Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 5Lymphoid 4CNS 3Myeloid 2Thoracic 1Sarcoma 1Plasma cell 1Dermatologic 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 159Carboplatin 147Cisplatin 130Pemetrexed 103Paclitaxel 89Nivolumab 71Radiotherapy 69Docetaxel 62Erlotinib Hydrochloride 58Gemcitabine 57Etoposide 44osimertinib 43Bevacizumab 43Cyclophosphamide 42durvalumab 41atezolizumab 35Cetuximab 33Radiosurgery 26130-nm albumin-bound paclitaxel 26fludarabine 23Ipilimumab 23Radiation 21Magnetic Resonance Spectroscopy 21Irinotecan 21Taxes 20Oxaliplatin 20Fluorouracil 20Gefitinib 19Everolimus 19Topotecan 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Blood Component Removal × Thoracic × Clear all
NCT00923741 2018-07-05

Effect of Talactoferrin in Adults With Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
10 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡